What is claimed is:

1. A compound of the formula:



(I)

wherein:

$R^1$ is selected from the group of hydrogen, $C_1$–$C_4$ alkyl, $C_1$–$C_4$ haloalkyl, $C_1$–$C_4$ heteroalkyl, $COR^{11}$, $CO_2R^{11}$, $SO_2R^{11}$, and $CONR^{11}R^{12}$;

$R^2$ and $R^3$ each independently is selected from the group of hydrogen, $C_1$–$C_6$ alkyl, and $C_1$–$C_6$ haloalkyl; or

$R^2$ and $R^3$ taken together form a cycloalkyl ring of from three to twelve carbons;

$R^4$ through $R^7$ each independently is selected from the group of hydrogen, F, Cl, Br, CN, $OR^{11}$, $C_1$–$C_4$ alkyl, $C_1$–$C_4$ haloalkyl, and $C_1$–$C_4$ heteroalkyl; or

$R^5$ and $R^7$ taken together form a bond; or

$R^6$ and $R^7$ taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

$R^8$ through $R^{10}$ each independently is selected from the group of hydrogen, F, Cl, Br, I, $NO_2$, CN, $OR^{11}$, $NR^{11}R^{12}$, $SR^{11}$, $COR^{11}$, $CO_2R^{11}$, $CONR^{11}R^{12}$, $C_1$–$C_8$ alkyl, $C_1$–$C_8$ heteroalkyl, $C_1$–$C_8$ haloalkyl, allyl, $C_2$–$C_8$ alkenyl and $C_2$–$C_8$ alkynyl;

$R^{11}$ and $R^{12}$ each is independently selected from the group of hydrogen, $C_1$–$C_4$ alkyl, $C_1$–$C_4$ heteroalkyl, and $C_1$–$C_4$ haloalkyl;

$R^{13}$ is hydrogen; or

$R^{13}$ and $R^{14}$ taken together form a bond;

$R^{14}$ through $R^{20}$ each independently is selected from the group of hydrogen, F, Cl, Br, $OR^{11}$, $C_1$–$C_4$ alkyl, $C_1$–$C_4$ haloalkyl, and $C_1$–$C_4$ heteroalkyl; or

$R^{14}$ and $R^{15}$ taken together are selected from the group of methylidene, carbonyl and thiocarbonyl; or

$R^{16}$ and $R^{17}$ taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene, ethylidene, carbonyl and thiocarbonyl; or

$R^{14}$ and $R^{16}$ taken together form a bond or "–O–" bridge; or

$R^{16}$ and $R^{18}$ taken together form a bond when n is 1; or

$R^{16}$ and $R^{19}$ taken together form a bond when n is 0;

$R^{21}$ is hydrogen; or

$R^{21}$ and $R^{20}$ taken together form a bond;

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt or prodrug thereof.

2. A compound according to claim 1, wherein $R^1$ is selected from the group of hydrogen, $C_1$–$C_4$ alkyl, $COR^{11}$, $SO_2R^{11}$, and $CONR^{11}R^{12}$.

3. A compound according to claim 1, wherein $R^2$ and $R^3$ each independently is selected from the group of $C_1$–$C_4$ alkyl, and $C_1$–$C_4$ haloalkyl.

4. A compound according to claim 1, wherein

$R^5$ and $R^7$ taken together form a bond;

$R^4$ and $R^6$ each independently is selected from the group of hydrogen, F, Cl, Br, CN, $OR^{11}$, $C_1$–$C_4$ alkyl, and $C_1$–$C_4$ haloalkyl.

5. A compound according to claim 1, wherein

$R^6$ and $R^7$ taken together are selected from the group of methylidene, and carbonyl;

$R^4$ and $R^5$ each independently is selected from the group of hydrogen, F, and $C_1$–$C_4$ alkyl.

6. A compound according to claim 1, wherein $R^8$ through $R^{10}$ each independently is selected from the group of hydrogen, F, Cl, Br, $NO_2$, CN, $OR^{11}$, $SR^{11}$, $C_1$–$C_6$ alkyl, $C_1$–$C_6$ heteroalkyl, and $C_1$–$C_6$ haloalkyl.

7. A compound according to claim 6, wherein $R^8$ through $R^{10}$ each independently is selected from the group of hydrogen, F, and $OR^{11}$.

8. A compound according to claim 1, wherein $R^{11}$ through $R^{12}$ each independently is selected from the group of hydrogen, and $C_1$–$C_4$ alkyl.

9. A compound according to claim 1, wherein

$R^{14}$ and $R^{16}$ taken together form a bond or "–O–" bridge;

$R^{15}$, $R^{17}$, $R^{18}$, $R^{19}$, $R^{20}$ each independently is selected from the group of hydrogen, F, Cl, $C_1$–$C_4$ alkyl, and $C_1$–$C_4$ haloalkyl.

10. A compound according to claim 1, wherein

$R^{16}$ and $R^{17}$ taken together are selected from the group of methylidene, mono-substituted methylidene, ethylidene and di-substituted methylidene;

$R^{14}$, $R^{15}$, $R^{18}$, $R^{19}$, $R^{20}$ each independently is selected from the group of hydrogen, F, Cl, $C_1$–$C_4$ alkyl, and $C_1$–$C_4$ haloalkyl.

11. A compound according to claim 1, wherein

$R^{16}$ and $R^{18}$ taken together form a bond when n is 1; or

$R^{16}$ and $R^{19}$ taken together form a bond when n is 0;

$R^{14}$, $R^{15}$, $R^{17}$, $R^{20}$ each independently is selected from the group of hydrogen, F, Cl, $C_1$–$C_4$ alkyl, and $C_1$–$C_4$ haloalkyl.

12. A compound according to claim 1, wherein said compound is selected from the group of:

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **24**);

(±)-(*5l,1'u*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **25**);

(+)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **27**);

(-)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **28**);

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **29**);

(±)-(*5l,1'u*)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **30**);

(+)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **32**);

(-)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **33**);

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **34**);

(±)-(*5l,1'u*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **35**);

(+)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **37**);

(-)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **38**);

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-methoxy-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **39**);

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2-dimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **41**);

(±)-(*5l,1'u*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2-dimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **42**);

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclopentenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **44**);

(±)-(*5l,1'u*)-5-(3-methyl-2-cyclopentenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **45**);

(±)-(*5l,1'l*)-5-(3,5,5-trimethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **47**);

(±)-(*5l,1'u*)-5-(3,5,5-trimethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **48**);

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **50**);

(±)-(*5l,1'u*)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **51**);

(±)-5-(3-methyl-3-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **52**);

(±)-5-(2-cyclopenta-1,3-dienyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **53**);

(±)-(*5l,1'l*)-5-(3-ethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **55**);

(±)-(*5l,1'u*)-5-(3-ethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **56**);

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-7-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **58**);

(±)-(*5l,1'u*)-5-(3-methyl-2-cyclohexenyl)-7-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **59**);

(±)-(*5l,1'l*)-5-(3-ethyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **61**);

(±)-(*5l,1'l*)-5-(3-ethylidenecyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **62**);

(±)-(*5l,1'l*)-5-(3-methyl-3-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **63**);

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-8-methoxy-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **64**);

(±)-(*5l,1'u*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-8-methoxy-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **65**);

(±)-(*5l,1'l*)-5-(2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **67**);

(±)-(*5l,1'u*)-5-(2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **68**);

(±)-5-(1-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **69**);

(±)-(*5l,1'l*)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **71**);

(+)-(*5l,1'l*)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **73**);

(-)-(*5l,1'l*)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **74**);

(±)-(*5l,1'l*)-5-(2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **75**);

(±)-(*5l,1'u*)-5-(2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **76**);

(±)-(*5l,1'l*)-5-(2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-4-methylidene-5*H*-chromeno[3,4-*f*]quinoline (compound **77**);

(±)-(*5l,1'l*)-5-(2-methylidenecyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **79**);

(±)-(*5l,1'u*)-5-(2-methylidenecyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **80**);

(±)-(*5l,1'l*)-5-(2-oxocyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **81**);

(±)-(*5l,1'u*)-5-(2-oxocyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **82**);

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-methoxy-1,2-dihydro-1,2,2,4-tetramethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **83**);

(±)-5-(2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **84**);

(±)-(*5l,1'l*)-5-(2,3-dimethyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **85**);

(±)-5-(3-methylidene-cyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **87**);

(±)-(*5l,1'u*)-5-(3-ethylidenecyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **88**);

(±)-*(5l,1'l)*- 5-(2-cycloheptenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-f]quinoline (Compound **89**);

(±)-*(5l,1'l)*- 5-(2-cyclooctenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-f]quinoline (Compound **91**);

(±)-*(5l,1'u)*- 5-(2-cyclooctenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-f]quinoline (Compound **92**);

(±)-*(5l,1'l)*- 5-(2,3-epoxy-3-methylcyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-f]quinoline (Compound **94**);

(±)-*(5l,1'l)*- 5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-4-methylene-5*H*-chromeno[3,4-f]quinolin-3-ol (Compound **95**);

(±)-*(5l,1'l)*- 5-(2,3-epoxy-2,3-dimethylcyclopentyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-f]quinoline (Compound **96**);

(±)-*(5l,1'u)*- 5-(2,3-epoxy-3-methylcyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-f]quinoline (Compound **97**); and

(±)-*(5l,1'l)*- 5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-5*H*-chromeno[3,4-f]quinolin-4-one (Compound **98**).

13. A compound according to claim 1, wherein said compound is selected from the group of:

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **24**);

(-)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **28**);

(-)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **33**);

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **34**);

(±)-(*5l,1'u*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **35**);

(-)-(*5l,1'l*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **38**);

(±)-(*5l,1'l*)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **50**);

(±)-(*5l,1'u*)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **51**);

(±)-(*5l,1'l*)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **71**);

(-)-(*5l,1'l*)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5*H*-chromeno[3,4-*f*]quinoline (compound **74**); and

(±)-*(5l,1'l)*- 5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-5*H*-chromeno[3,4-f]quinolin-4-one (Compound **98**).

14. A compound of the formula:




(II)

wherein:

$R^2$ and $R^3$ each independently is selected from the group of hydrogen, $C_1$–$C_4$ alkyl, and $C_1$–$C_4$ haloalkyl;

$R^6$ is selected from the group of hydrogen, F, Cl, Br, CN, $OR^{11}$, $C_1$–$C_4$ alkyl, and $C_1$–$C_4$ haloalkyl;

$R^8$ and $R^{10}$ each independently is selected from the group consisting of hydrogen, F, Cl, Br, CN, $OR^{11}$, $NR^{11}R^{12}$, $SR^{11}$, $COR^{11}$, $C_1$–$C_4$ alkyl, $C_1$–$C_4$ heteroalkyl, $C_1$–$C_4$ haloalkyl, allyl, and $C_2$–$C_4$ alkenyl;

$R^{11}$ and $R^{12}$ each is independently selected from the group of hydrogen, $C_1$–$C_4$ alkyl, $C_1$–$C_4$ heteroalkyl, and $C_1$–$C_4$ haloalkyl;

$R^{14}$, $R^{15}$, $R^{18}$, $R^{22}$, $R^{23}$, $R^{24}$ each independently is selected from the group of hydrogen, F, Cl, $OR^{11}$, $C_1$–$C_4$ alkyl, $C_1$–$C_4$ haloalkyl, and $C_1$–$C_4$ heteroalkyl;

$R^{22}$, $R^{23}$, $R^{24}$ together consists of not more than 3 carbon atoms;

$R^{16}$ taken together with one of $R^{14}$, $R^{18}$, and $R^{22}$ form a bond or "–O–" bridge;

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt or prodrug thereof.

15. A compound according to claim 14, wherein

$R^2$ and $R^3$ each independently is selected from the group of $C_1$–$C_4$ alkyl;

$R^6$ is selected from the group of F, Cl, Br, $C_1$–$C_4$ alkyl, and $C_1$–$C_4$ haloalkyl;

$R^8$ and $R^{10}$ each independently is selected from the group of hydrogen, F, Cl, Br, CN, $OR^{11}$, $C_1$–$C_4$ alkyl, and $C_1$–$C_4$ haloalkyl;

$R^{11}$ and $R^{12}$ each is independently selected from the group of hydrogen, $C_1$–$C_4$ alkyl;

$R^{14}$, $R^{15}$, $R^{18}$, $R^{22}$, $R^{23}$, $R^{24}$ each independently is selected from the group of hydrogen, F, $C_1$–$C_4$ alkyl;

$R^{16}$ taken together with one of $R^{14}$, $R^{18}$, and $R^{22}$ form a bond or "–O–" bridge;

n is 0, 1, or 2.

16. A compound according to claim 15, wherein

$R^2$ and $R^3$ each independently is $CH_3$;

$R^6$ is selected from the group of F, Cl, Br, $CH_3$, $CH_2CH_3$, and $CF_3$;

$R^8$ is hydrogen or F;

$R^{10}$ is selected from the group of hydrogen, F, Cl, Br, CN, OH, $OCH_3$, $CH_3$, $CH_2CH_3$, and $CF_3$;

$R^{14}$ and $R^{16}$ taken together form a bond or "–O–" bridge;

$R^{15}$, $R^{18}$, $R^{22}$, $R^{23}$, and $R^{24}$ each independently is hydrogen or $CH_3$.

17. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula:



(I)

wherein:

$R^1$ is selected from the group of hydrogen, $C_1$–$C_4$ alkyl, $C_1$–$C_4$ haloalkyl, $C_1$–$C_4$ heteroalkyl, $COR^{11}$, $CO_2R^{11}$, $SO_2R^{11}$, and $CONR^{11}R^{12}$;

$R^2$ and $R^3$ each independently is selected from the group of hydrogen, $C_1$–$C_6$ alkyl, and $C_1$–$C_6$ haloalkyl; or

$R^2$ and $R^3$ taken together form a cycloalkyl ring of from three to twelve carbons;

$R^4$ through $R^7$ each independently is selected from the group of hydrogen, F, Cl, Br, CN, $OR^{11}$, $C_1$–$C_4$ alkyl, $C_1$–$C_4$ haloalkyl, and $C_1$–$C_4$ heteroalkyl; or

$R^5$ and $R^7$ taken together form a bond; or

$R^6$ and $R^7$ taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

$R^8$ through $R^{10}$ each independently is selected from the group of hydrogen, F, Cl, Br, I, $NO_2$, CN, $OR^{11}$, $NR^{11}R^{12}$, $SR^{11}$, $COR^{11}$, $CO_2R^{11}$, $CONR^{11}R^{12}$, $C_1$–$C_8$ alkyl, $C_1$–$C_8$ heteroalkyl, $C_1$–$C_8$ haloalkyl, allyl, $C_2$–$C_8$ alkenyl and $C_2$–$C_8$ alkynyl;

$R^{11}$ and $R^{12}$ each is independently selected from the group of hydrogen, $C_1$–$C_4$ alkyl, $C_1$–$C_4$ heteroalkyl, and $C_1$–$C_4$ haloalkyl;

$R^{13}$ is hydrogen; or

$R^{13}$ and $R^{14}$ taken together form a bond;

$R^{14}$ through $R^{20}$ each independently is selected from the group of hydrogen, F, Cl, Br, $OR^{11}$, $C_1$–$C_4$ alkyl, $C_1$–$C_4$ haloalkyl, and $C_1$–$C_4$ heteroalkyl; or

$R^{14}$ and $R^{15}$ taken together are selected from the group of methylidene, carbonyl and thiocarbonyl; or

$R^{16}$ and $R^{17}$ taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene, ethylidene, carbonyl and thiocarbonyl; or

$R^{14}$ and $R^{16}$ taken together form a bond or "–O–" bridge; or

$R^{16}$ and $R^{18}$ taken together form a bond when n is 1; or

$R^{16}$ and $R^{19}$ taken together form a bond when n is 0;

$R^{21}$ is hydrogen; or

$R^{21}$ and $R^{20}$ taken together form a bond;

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt or prodrug thereof.

18. A pharmaceutical composition according to claim 17, wherein $R^1$ is selected from the group of hydrogen, $C_1$–$C_4$ alkyl, $COR^{11}$, $SO_2R^{11}$, and $CONR^{11}R^{12}$.

19. A pharmaceutical composition according to claim 17, wherein $R^2$ and $R^3$ each independently is selected from the group of $C_1$–$C_4$ alkyl, and $C_1$–$C_4$ haloalkyl.

20. A pharmaceutical composition according to claim 17, wherein

$R^5$ and $R^7$ taken together form a bond;

$R^4$ and $R^6$ each independently is selected from the group of hydrogen, F, Cl, Br, CN, $OR^{11}$, $C_1$–$C_4$ alkyl, and $C_1$–$C_4$ haloalkyl.

21. A pharmaceutical composition according to claim 17, wherein

$R^6$ and $R^7$ taken together are selected from the group of methylidene, and carbonyl;

$R^4$ and $R^5$ each independently is selected from the group of hydrogen, F, and $C_1$–$C_4$ alkyl.

22. A pharmaceutical composition according to claim 17, wherein $R^8$ through $R^{10}$ each independently is selected from the group of hydrogen, F, Cl, Br, $NO_2$, CN, $OR^{11}$, $SR^{11}$, $C_1$–$C_6$ alkyl, $C_1$–$C_6$ heteroalkyl, and $C_1$–$C_6$ haloalkyl.

23. A pharmaceutical composition according to claim 22, wherein $R^8$ through $R^{10}$ each independently is selected from the group of hydrogen, F, and $OR^{11}$.

24. A pharmaceutical composition according to claim 17, wherein $R^{11}$ through $R^{12}$ each independently is selected from the group of hydrogen, and $C_1$–$C_4$ alkyl.

25. A pharmaceutical composition according to claim 17, wherein

$R^{14}$ and $R^{16}$ taken together form a bond or "–O–" bridge;

$R^{15}$, $R^{17}$, $R^{18}$, $R^{19}$, $R^{20}$ each independently is selected from the group of hydrogen, F, Cl, $C_1$–$C_4$ alkyl, and $C_1$–$C_4$ haloalkyl.

26. A pharmaceutical composition according to claim 17, wherein

$R^{16}$ and $R^{17}$ taken together are selected from the group of methylidene, mono-substituted methylidene, ethylidene, and di-substituted methylidene;

$R^{14}$, $R^{15}$, $R^{18}$, $R^{19}$, $R^{20}$ each independently is selected from the group of hydrogen, F, Cl, $C_1$–$C_4$ alkyl, and $C_1$–$C_4$ haloalkyl.

27. A pharmaceutical composition according to claim 17, wherein

$R^{16}$ and $R^{18}$ taken together form a bond when n is 1; or

$R^{16}$ and $R^{19}$ taken together form a bond when n is 0;

$R^{14}$, $R^{15}$, $R^{17}$, $R^{20}$ each independently is selected from the group of hydrogen, F, Cl, $C_1$–$C_4$ alkyl, and $C_1$–$C_4$ haloalkyl.

28. A method of treating an individual having a condition mediated by a progesterone receptor comprising administering to said individual a pharmaceutically effective amount of a compound according to any one of claims 1, 12 or 14.

29. A method of treating an individual having a condition mediated by a progesterone receptor comprising administering to said individual a pharmaceutically effective amount of a compound represented by formula (I):




(I)

wherein:

$R^1$ is selected from the group of hydrogen, $C_1$–$C_4$ alkyl, $C_1$–$C_4$ haloalkyl, $C_1$–$C_4$ heteroalkyl, $COR^{11}$, $CO_2R^{11}$, $SO_2R^{11}$, and $CONR^{11}R^{12}$;

$R^2$ and $R^3$ each independently is selected from the group of hydrogen, $C_1$–$C_6$ alkyl, and $C_1$–$C_6$ haloalkyl; or

$R^2$ and $R^3$ taken together form a cycloalkyl ring of from three to twelve carbons;

$R^4$ through $R^7$ each independently is selected from the group of hydrogen, F, Cl, Br, CN, $OR^{11}$, $C_1$–$C_4$ alkyl, $C_1$–$C_4$ haloalkyl, and $C_1$–$C_4$ heteroalkyl; or

$R^5$ and $R^7$ taken together form a bond; or

$R^6$ and $R^7$ taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

$R^8$ through $R^{10}$ each independently is selected from the group of hydrogen, F, Cl, Br, I, $NO_2$, CN, $OR^{11}$, $NR^{11}R^{12}$, $SR^{11}$, $COR^{11}$, $CO_2R^{11}$, $CONR^{11}R^{12}$, $C_1$–$C_8$ alkyl, $C_1$–$C_8$ heteroalkyl, $C_1$–$C_8$ haloalkyl, allyl, $C_2$–$C_8$ alkenyl and $C_2$–$C_8$ alkynyl;

$R^{11}$ and $R^{12}$ each is independently selected from the group of hydrogen, $C_1$–$C_4$ alkyl, $C_1$–$C_4$ heteroalkyl, and $C_1$–$C_4$ haloalkyl;

$R^{13}$ is hydrogen; or

$R^{13}$ and $R^{14}$ taken together form a bond;

$R^{14}$ through $R^{20}$ each independently is selected from the group of hydrogen, F, Cl, Br, $OR^{11}$, $C_1$–$C_4$ alkyl, $C_1$–$C_4$ haloalkyl, and $C_1$–$C_4$ heteroalkyl; or

$R^{14}$ and $R^{15}$ taken together are selected from the group of methylidene, carbonyl and thiocarbonyl; or

$R^{16}$ and $R^{17}$ taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene, ethylidene, carbonyl and thiocarbonyl; or

$R^{14}$ and $R^{16}$ taken together form a bond or "–O–" bridge; or

$R^{16}$ and $R^{18}$ taken together form a bond when n is 1; or

$R^{16}$ and $R^{19}$ taken together form a bond when n is 0;

$R^{21}$ is hydrogen; or

$R^{21}$ and $R^{20}$ taken together form a bond;

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt or prodrug thereof.

30. A method of treating an individual having a condition mediated by a progesterone receptor comprising administering to said individual a pharmaceutically effective amount of a compound represented by formula (II):




(II)

wherein:

$R^2$ and $R^3$ each independently is selected from the group of hydrogen, $C_1$–$C_4$ alkyl, and $C_1$–$C_4$ haloalkyl;

$R^6$ is selected from the group of hydrogen, F, Cl, Br, CN, $OR^{11}$, $C_1$–$C_4$ alkyl, and $C_1$–$C_4$ haloalkyl;

$R^8$ and $R^{10}$ each independently is selected from the group of hydrogen, F, Cl, Br, CN, $OR^{11}$, $NR^{11}R^{12}$, $SR^{11}$, $COR^{11}$, $C_1$–$C_4$ alkyl, $C_1$–$C_4$ heteroalkyl, $C_1$–$C_4$ haloalkyl, allyl, and $C_2$–$C_4$ alkenyl;

$R^{11}$ and $R^{12}$ each is independently selected from the group of hydrogen, $C_1$–$C_4$ alkyl, $C_1$–$C_4$ heteroalkyl, and $C_1$–$C_4$ haloalkyl;

$R^{14}$, $R^{15}$, $R^{18}$, $R^{22}$, $R^{23}$, $R^{24}$ each independently is selected from the group of hydrogen, F, Cl, $OR^{11}$, $C_1$–$C_4$ alkyl, $C_1$–$C_4$ haloalkyl, and $C_1$–$C_4$ heteroalkyl;

$R^{22}$, $R^{23}$, $R^{24}$ together consists of not more than 3 carbon atoms;

$R^{16}$ taken together with one of $R^{14}$, $R^{18}$, and $R^{22}$ form a bond or "–O–" bridge;

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt or prodrug thereof.

31. A method according to claim 28, wherein said condition is selected from the group of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flushes, mood disorders, meningiomas, hormone-dependent cancers and female osteoporosis.

32. A method according to claim 28, wherein said condition is alleviated with female hormone replacement therapy.

33. A method of modulating fertility in an individual comprising administering to said individual a pharmaceutically effective amount of a compound according to any one of claims 1, 12 or 14.

34. A method of providing contraception to an individual comprising administering to said individual a pharmaceutically effective amount of a compound according to any one of claims 1, 12 or 14.

35. A method of modulating a progesterone receptor in an individual comprising administering to said individual a compound according to any one of claims 1, 12, or 14 in an amount effective to modulate a progesterone receptor.

36. A method according to claim 35, wherein said modulation is activation.

37. A method according to claim 36, wherein said compound provides at least 50% maximal activation of the progesterone receptor at a concentration of less than 100 nM.

38. A method according to claim 36, wherein said compound provides at least 50% maximal activation of the progesterone receptor at a concentration of less than 50 nM.

39. A method according to claim 36, wherein said compound provides at least 50% maximal activation of the progesterone receptor at a concentration of less than 20 nM.

40. A method according to claim 36, wherein said compound provides at least 50% maximal activation of the progesterone receptor at a concentration of less than 10 nM.

41. A method of treating cancer, comprising administering to a patient in need thereof an effective amount of a compound according to any one of claims 1, 12 or 14.

42. A method according to claim 41, wherein said cancer is selected from the group of ovarian cancer, breast cancer, endometrium cancer and prostate cancer.

43. A method of determining the presence of a progesterone receptor (PR) in a cell or cell extract comprising (a) labeling a compound according to any one of claims 1, 12 or 14; (b) contacting the cell or cell extract with said labeled compound; and (c) testing the contracted cell or cell extract to determine the presence of progesterone receptor.